SPOTLIGHT: FDA rejects Glaxo depression drug

The FDA has turned thumbs down on GlaxoSmithKline's gepirone ER for major depression. Glaxo had licensed the drug from Fabre-Kramer after Akzo Nobel had bowed out of an earlier partnership. Analysts gave the drug some significant earnings potential, but have been wary of the drug's earlier problems with the FDA. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.